The Efficacy, Tolerability and Safety of Donepezil (Aricept) in Parkinson's Disease Patients With Dementia
Phase 3
Completed
- Conditions
- Dementia With Parkinson's Disease
- Registration Number
- NCT00165815
- Lead Sponsor
- Eisai Limited
- Brief Summary
A randomised, double-blind, 3-arm parallel group study comparing Aricept® with placebo.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method PD patients with dementia will be screened up to 4 weeks prior to initiating dose administration. Baseline measurement on efficacy measures will be conducted at baseline, after which the first dose of study medication will be administered.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (4)
Belfast City Hospital
🇮🇪Belfast, Ireland
Unit 20 Black Poo Technology Centerl
🇮🇪Blackpool, Ireland
Parkinson Klinik Wolfach
🇩🇪Wolfach, Germany
Allgemeines Krankenhaus Barmbeck
🇩🇪Hamburg, Hambug, Germany